MERZ-THERAPEUTICS
Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfampridine) is Food and Drug Administration (FDA) approved in the U.S. and commercialized as FAMPYRA in the European Union and other territories throughout the world. This transaction was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code. The completion of this deal, valued at USD 185 million in cash, bolsters Merz Therapeutics’ market position by enhancing offerings for people living with Parkinson’s disease and expanding into the multiple sclerosis (MS) space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240710459851/en/
“The addition of INBRIJA and (F)AMPYRA to the treatment portfolio underlines Merz Therapeutics’ global Pivot for Growth strategy to both evolve the current portfolio and achieve critical scale and global reach,” said Stefan König, CEO of Merz Therapeutics. “Merz Therapeutics is well poised to build on what we have accomplished in the specialty neurology space, strengthening our market position in Parkinson’s disease and expanding into the MS segment. This deal demonstrates Merz Therapeutics’ interest and ability to acquire assets that will deliver greater, sustainable outcomes for more people living with neurological disorders.”
INBRIJA and (F)AMPYRA are projected to immediately add topline revenue which will enhance Merz Therapeutics’ ability to accelerate clinical development of its existing and new assets. Its U.S. business is forecasted to contribute more than 75% of INBRIJA’s and (F)AMPYRA’s total global revenues over the next 10 years. Additionally, the company expects the U.S. workforce to increase by more than 50%.
INBRIJA is a significant advancement for people living with Parkinson's disease as it provides an on-demand, inhalable form of levodopa, offering an effective way to manage “OFF” episodes. This method of delivery, achievable through the innovative and proprietary technology platform, ARCUS®, is especially valuable for people who need rapid relief from their symptoms, which cannot be achieved reliably through oral intake.
(F)AMPYRA is the first medication approved for improving walking in patients with MS, demonstrated by an improved walking ability.
“Expanding the portfolio with INBRIJA, including plans for worldwide product roll-out, and (F)AMPYRA allows Merz Therapeutics the opportunity to leverage its experience in the specialty neurology space to serve even more patients living with neurological disorders and support the physicians who treat them,” said Stefan Albrecht, Chief Scientific and Medical Officer. “Because these treatments complement the company’s product portfolio and distribution system, we are well positioned to support patients who depend on these products seamlessly.”
About INBRIJA
INBRIJA® is an inhaled prescription levodopa medicine used to treat the return of Parkinson’s symptoms (known as “OFF” episodes) in people with Parkinson’s disease who are treated with carbidopa/levodopa medicines. It does not replace the regular carbidopa/levodopa medicines. INBRIJA is not to be used by people with Parkinson’s disease who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks. The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea and change in the color of saliva or spit.
About FAMPYRA
FAMPYRA® is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine). FAMPYRA is indicated in the European Union for the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 4-7). In clinical trials, the highest incidence of adverse reactions identified with FAMPYRA given at the recommended dose was urinary tract infection. Other adverse drug reactions identified were mainly divided between neurological disorders such as insomnia, balance disorder, dizziness, paraesthesia and headache, and gastrointestinal disorders including nausea, dyspepsia and constipation. In post-marketing experience, there have been reports of seizure. Please see FAMPYRA EPAR for more information.
About AMPYRA
AMPYRA® is an extended-release tablet formulation of dalfampridine (4-aminopyridine, 4-AP or fampridine). AMPYRA is a potassium channel blocker approved as a treatment to help improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The most common side effects for AMPYRA in MS patients were urinary tract infection; trouble sleeping; dizziness; headache; nausea; weakness; back pain; problems with balance; multiple sclerosis relapse; burning, tingling, or itching of your skin; irritation in your nose and throat; constipation; indigestion; and pain in your throat. Please see the AMPYRA Patient Medication Guide for more information.
About Merz Therapeutics
Merz Therapeutics is dedicated to improving the lives of patients around the world. With its relentless research, development and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.
Please visit www.merztherapeutics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710459851/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Launches Silicon Shoring: an AI-Powered Software Delivery Model to Optimise and Automate the Entire Software Development Life Cycle15.5.2025 11:00:00 CEST | Press release
Reply,a global systems integrator and technology consulting firm, has launched Silicon Shoring, a new software delivery model powered by Artificial Intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515940305/en/ Silicon Shoring is an AI-Powered Software Delivery model designed to optimise and automate the entire Software Development Life Cycle. Silicon Shoring enhances how companies source, build, and manage software by integrating Generative AI agents across the entire Software Development Life Cycle (SDLC) - from requirements and code generation to testing, deployment, operations, and monitoring. The model replaces traditional software development process with a flexible, intelligent, and automated delivery approach, blending AI with human expertise to deliver scalable, high-quality software at speed. Silicon Shoring delivers measurable business value. Reply’s experience demonstrates a significant acceleratio
JPMorganChase to Expand Paris Office Space15.5.2025 10:30:00 CEST | Press release
Firm signs a long term lease on a new building at 37 Place du Marché Saint-Honoré, while retaining its French headquarters at 14 Place VendômeTotalling 16,000 square-metres, this new building will have large open floors and modern amenities across five storeys and a capacity of 1,000 employeesNew office reflects a continued long term commitment to the city, and reflects wider investments in France where the firm has invested over $100 million through business and philanthropic partnerships since 2018 JPMorganChase today announces that it has signed a lease on a new building in Paris at 37 Place du Marché Saint-Honoré as the firm has passed over 1,000 employees in the city. The new office is situated behind the bank’s headquarters at 14 Place Vendôme, and is opposite 21 Place du Marché Saint-Honoré, where the bank also has employees. While this investment will see the firm reduce the buildings it occupies in central Paris from six to just three, overall office space will increase signif
Arion Bank Strengthens Compliance With Volante Technologies’ Payments as a Service15.5.2025 10:16:00 CEST | Press release
Iceland’s leading bank strengthens its modern payments infrastructure and partners with Volante to support long-term innovation and growth Volante Technologies, the global leader in Payments as a Service (PaaS), announced a strategic partnership with Iceland’s leading financial institution, Arion Bank, to modernise and future-proof the bank's payments infrastructure, solidify its regulatory response, and prepare for an increase in transaction volume as part of its growth plan. Arion Bank is one of Iceland's leading financial institutions and the third-largest bank in the country by assets. It offers a wide range of services in retail, corporate, and investment banking, providing smart and reliable financial solutions to individuals and businesses alike. The bank sought to evolve its current payments hub by adopting a modern, API-driven, and scalable solution designed to support multi-rail processing and seamless integration with the emerging payments ecosystem. By partnering with Volan
ITEN and A*STAR IME Announce Breakthrough in Solid-State Battery Integration for Advanced Packaging15.5.2025 09:00:00 CEST | Press release
ITEN, a global leader in micro solid-state batteries, and A*STAR Institute of Microelectronics (A*STAR IME), a leader in advanced packaging research, have announced a groundbreaking achievement for the integration of ITEN’s micro batteries using A*STAR IME’s cutting-edge advanced packaging platform. This milestone paves the way for in-package energy storage solutions, enabling more efficient, compact, and reliable system-in-package (SiP) designs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515958544/en/ Revolutionizing Energy Storage and Advanced Packaging This breakthrough innovation represents a significant leap forward in SiP technology. By embedding ITEN’s high-performance solid-state batteries at the wafer level, ITEN and A*STAR IME have successfully demonstrated integrating non-volatile energy storage directly using advanced packaging. This enables seamless integration, elevating energy efficiency and operational
Equiduct Expands into the Swiss Market15.5.2025 08:00:00 CEST | Press release
Equiduct, the leading pan-European retail-focused exchange, today announced the launch of its Swiss equity segment, providing retail brokers using Apex with access to 138 of the most liquid Swiss-listed stocks — all priced in Swiss francs (CHF). The newly available securities include heavily traded household names such as Nestlé S.A., Novartis AG, UBS Group AG, and ABB Ltd. Liquidity on the Swiss segment of Equiduct is supported by Apex market makers Virtu Financial, Hudson River Trading, and Optiver. As with all executions on Equiduct, trades on the Swiss segment will benefit from fully interoperable clearing via Equiduct’s pan-European network of CCPs: LCH Ltd, Cboe Clear, and the local Swiss CCP SIX x-clear. This expansion follows formal approval from the Swiss Financial Market Supervisory Authority (FINMA), which recognises Börse Berlin and Equiduct as a regulated market under Article 41 of FinfraG. This status also paves the way for Swiss banks and brokers to join Equiduct as dire
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom